Marta Rysz completed her MSc studies in Biotechnology at the Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University in 2010 (at lab of Prof. Joanna Bereta). Her project concerned designing and optimizing a phage display protocol for the enrichment of phages expressing single chain variable antibody fragments (scFv) that would bind and inhibit transmembrane protein activity. In the course of her MSc, she had also a one-year long training as a Socrates student at the Imperial College London (Kennedy Institute of Rheumatology), where she was involved in establishing a protocol for recombinant expression and purification of a proteinase known to be involved in development of arthritis. In 2011 she started her PhD in the Lab of Wladyslawa Daniel (Pharmacokinetics and Drug Metabolism) at the Institute of Pharmacology, Polish Academy of Sciences (IP, PAS, Krakow, Poland) to investigate the role of the brain serotonergic system in the expression and activity of cytochrome P450 in the liver. After PhD graduation in 2015 she stayed within the Pharmacokinetics and Drug Metabolism group (IP PAS) as a Research Fellow. Marta joined the group of Biopharmacy of Prof. Henriette Meyer zu Schwabedissen in March 2021. She currently works on characterizing the OATP2B1 transporter in a novel rat model.